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ABSTRACT
Objectives: To examine the funding for cerebral palsy
(CP) research in Australia, as compared with the
National Institutes of Health (NIH).
Design: Observational study.
Setting: For Australia, philanthropic funding from
Cerebral Palsy Alliance Research Foundation (CPARF)
(2005–2015) was compared with National Health and
Medical Research Council (NHMRC, 2000–2015) and
Australian Research Council (ARC, 2004–2015) and
CPARF and NHMRC funding were compared with NIH
funding (USA).
Participants: Cerebral Palsy researchers funded by
CPARF, NHMRC or NIH.
Results: Over 10 years, total CPARF philanthropic
funding was $21.9 million, including people,
infrastructure, strategic and project support. As
competitive grants, CPARF funded $11.1 million,
NHMRC funded $53.5 million and Australian Research
Council funded $1.5 million. CPARF, NHMRC and NIH
funding has increased in real terms, but only the NIH
statistically significantly increased in real terms (mean
annual increase US$4.9 million per year, 95% CI 3.6 to
6.2, p<0.001). The NHMRC budget allocated to CP
research remained steady over time at 0.5%. A network
analysis indicated the relatively small number of CP
researchers in Australia is mostly connected through
CPARF or NHMRC funding.
Conclusions: Funding for CP research from the
Australian government schemes has stabilised and CP
researchers rely on philanthropic funding to fill this
gap. In comparison, the NIH is funding a larger
number of CP researchers and their funding pattern is
consistently increasing.
INTRODUCTION
Medical research delivers large health, social
and economic beneﬁts.1 As countries con-
tinue to invest in health, global investment in
medical research continues to climb, especially
in high-income countries.2 Disproportionate
amounts of research funding are spent on:
(1) conditions with relevance in high-income
countries even though the disease burden
is greater in low-income countries2 and
(2) prevalent and costly public health pro-
blems secure government funding priorities
in preference to rarer diseases. Philanthropic
funding for global research is crucial,3 and
the important role of research patient orga-
nisations has been recognised for brain
disorders in Canada4 and rare diseases in
Australia.5 In the USA, the independent
organisation Patient-Centered Outcomes
Research Institute (PCORI) provides funding
for patient-focused research that encourage
collaborations across sectors to provide
beneﬁt directly to patients, including new
projects in 2016 for people and families
living with CP.
CP is the most common childhood physical
disability with a prevalence of 3.1 per 1000
births in four areas of the USA,6 compared
with 2.1 per 1000 live births in Australia.7 In
the last 10 years, the Australian rate has
decreased from 1-in-526 births to 1-in-625
births, alongside reductions in co-occurring
Strengths and limitations of this study
▪ This study examines the current state of philan-
thropic and competitive funding for cerebral
palsy (CP) research in Australia, and the direc-
tion that competitive funding for CP research is
moving in relation to National Institutes of Health
(NIH) funding in the USA.
▪ In Australia, the analysis of funding from
National Health and Medical Research Council
(NHMRC) and the Australian Research Council
(ARC) is limited by the public availability of
summary spreadsheets and final project sum-
maries and the specific ARC exclusion of
medical and clinical research.
▪ The findings are an underestimate of CP funding
as the search for grants was based on strict
keyword searches, and the comparison between
Australia and the USA is limited to competitive
grants (NHMRC and NIH). The analysis is also
limited due to the exclusion of other philan-
thropic or charitable organisations in Australia
and the USA.
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epilepsy (20% reduction), intellectual disability (17%)
and wheelchair use (15%).8 These reductions are evi-
dence of the cumulative translation of research ﬁndings
from projects that started with CP funding.
Additional research impacts include reducing the col-
lective economic costs of CP on the Australian commu-
nity, estimated in 2007 to be almost $4 billion annually.9
In Australia, people living with CP and their families
have clearly articulated prevention and cure of CP as
their highest priorities for future research as identiﬁed
by a Delphi study.10 Yet the public and health profes-
sionals’ perception regarding CP has historically been a
disability that cannot be prevented or cured, and so the
research has focused on interventions aimed at improv-
ing quality of life. A key role for CP researchers and CP
advocates worldwide is to challenge these public percep-
tions.8 Prevention and cure may include a reduction in
CP severity where people are mobile and do not require
a wheelchair or no longer have epilepsy.11
The aim of this study is to examine the current state
of philanthropic and competitive funding for CP
research in Australia, and the direction that competitive
funding for CP research is moving in relation to the
USA. In the past decade, the focus of Australian CP
research has expanded from interventions and therap-
ies, to prevention and cure of CP. In comparison with
the NIH funding for CP research,12 13 Australia has a
smaller yet growing community of CP researchers seeking
funding. This study will examine the funding for CP
research in Australia from the single philanthropic
funding body speciﬁcally for CP research and the major
competitive funding schemes from the government. It
will examine: (1) whether CP funding is increasing in
real terms; (2) whether CP funding in Australia is increas-
ing compared with the NIH and (3) the Australian com-
munity of CP researchers and how these networks have
interacted to successfully obtain funding.
METHOD
To obtain a complete picture of competitive and philan-
thropic funding of CP research in Australia, information
was sought from Cerebral Palsy Alliance (CPA), NHMRC
and ARC.
Funding bodies
The CPA is a not-for-proﬁt organisation established by
parents that provides services to clients with CP and
their families living in the Australian state of New South
Wales and Australian Capital Territory, and was formerly
known as The Spastic Centre of New South Wales as
established in 1945.14 The Cerebral Palsy Alliance
Research Foundation (CPARF) was established in 2005
from ongoing fund raising and donor support, and from
2011 receives donations from the annual STEPtember
global charity event. CPARF established the Research
Institute in 2005 to be dedicated to CP research, awarded
the ﬁrst grants in 2006, hosted the International CP
Conference in 2009 and subsequently funded Australia’s
ﬁrst Professorial Chair of Cerebral Palsy as a university
appointment.15
The Australian Government provides competitive
grant funding through: (1) NHMRC as the major
funding body for health and medical research; and (2)
ARC funds research and innovation, including industry
partnerships, speciﬁcally excluding medical, clinical or
dental research. In the past decade, and relative to
NHMRC and ARC, CPARF is the new funding scheme
that is speciﬁcally for CP research.
Funding type
Cerebral Palsy Alliance Research Foundation (CPARF)
Total CPARF funding was categorised as: (1) people and
infrastructure; (2) strategic grants to pursue prevention
and cure and (3) competitive grants.15 The CPARF com-
petitive grants programme is administered through a
formal application process including external peer
review. The research priorities for the programme are
prevention and cure of CP, and novel interventions.
From 2006 to 2015, CPARF provided two competitive
funding schemes: People (ie, Career Development) and
Project grants. People grants cofunded with the
NHMRC (n=9) were excluded from the CPARF analysis
to avoid double counting; these nine grants are included
with the NHMRC.
National Health and Medical Research Council (NHMRC)
NHMRC data were grouped into Centre, People or
Project grants. Centre grants included: Centre for
Research Excellence, Centre for Clinical Excellence,
Development and Programme. People grants included:
Fellowships (Early Career, Career Development, Research,
Translating Research into Practice) and Postgraduate
Scholarships. Project grants included Project and
Partnership schemes. In 2015, two sources of NHMRC
data were used: spreadsheet of funding expenditure per
year (2000–2015) and ﬁnal reports for People or Project
grants (2004–2012).16 17
NHMRC inclusion/exclusion criteria: We extracted
CP-related grants from the complete list of NHMRC
grants by searching for the keywords ‘cerebral’ and
‘palsy’, or the phrase ‘neonatal encephalopathy’ in the
ﬁnal reports. The absence of these keywords/phrase in
the NHMRC data excluded grants that may be known to
beneﬁt CP research, resulting in an underestimate of
total CP funding. For the 2015 NHMRC data, only the
lead researcher was listed in the public domain and no
data were available on the funding breakdown by year,
so we assumed the total income was spread equally over
the (future) funded years.
NHMRC ﬁnal reports were available for 2004–2012
only; the datasets were publicly accessible from the
NHMRC website in 2015. The search of the ﬁnal reports
uncovered projects that were only partly related to CP,
for example, CP was referred to as a potential conse-
quence but was not the main aim; these projects were
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excluded from the analysis. For grants that were not
solely dedicated to CP a fraction of funding was used,
for example, CP was one of four conditions mentioned
in the ﬁnal report, the total funding amount was divided
by four and that quarter amount was included in the
analysis. These were crude adjustments, but avoided
overestimating the total funding for CP research.
Clinical trials that were not solely focused on CP, or may
have translated to CP in the future, were excluded.
Additional NHMRC spreadsheets were searched for
funding allocations by health condition or disease; this
data is a combination of information provided by the
researchers in their original applications and subjective
determinations by internal NHMRC processes.16
Australian Research Council (ARC)
ARC competitive grant schemes for People (Future
Fellowship) and Projects (Discovery and Linkage) specif-
ically exclude medical, clinical and dental research that
examines the understanding or treatment of a health
condition or disease.18 ARC funded projects from 2004
to 2015 were searched for the keywords ‘cerebral’ and
‘palsy’; the medical phrase ‘neonatal encephalopathy’
was not used, given the ARC exclusion of medical
research. Grants using the keyword ‘disability’, and not
speciﬁcally ‘cerebral palsy’ were excluded.
National Institutes of Health (NIH)
NIH summary data were provided by Wu et al12 on CP
funding among all NIH-funded studies from 2001 to
2012 in the USA. Wu et al12 searched the NIH databases
Research Portfolio Online Reporting Tools Expenditures
and Results, and Research, Condition, and Disease
Categorization for the key phrase ‘cerebral palsy’, and
summarised the data as basic or clinical research.12 The
NIH funding is shown in this study as the combined
total amount, and in terms of award year rather than
expenditure year.
Funding trends
Plots for funding trends are expenditure over time.
There are two ways of displaying funding over time: (1)
by the year the grant was awarded and (2) by the year of
expenditure. Our preference is to show the results by
expenditure year as this is a better reﬂection of overall
research activity. For the 2015 NHMRC grants where the
annual expenditure was unavailable, the total amount
was spread evenly over the years of the project. For
example, a project with a total budget of $300 000
running from 2015 to 2017 would have $100 000 in each
year. Annual totals were used to show the overall levels
of expected research activity over time.
Annual funding ﬁgures were adjusted for inﬂation
using the Australian consumer price index (US index
for NIH data), which reﬂects the historic change in pur-
chasing power over time.19 We compared the similarity
in trends over time using time series plots, calculated
the Pearson correlation between the three funding
agencies and used linear regression to look for a statis-
tical increase in funding over time. All analyses were
completed using R V.3.2.2 (R Core Team. R: A Language
and Environment for Statistical Computing. Vienna,
Austria: R Foundation for Statistical Computing, 2015.
https://www.R-project.org).
Network analysis
The network analysis examined the links between
researchers who won funding from CPARF or NHMRC.
If two researchers were investigators on the same grant
they are linked in the network diagram. Researchers
were anonymised by number ranking according to their
overall income from the respective funding body, with
the ‘number 1’ assigned to the highest funding earner.
The ‘igraph’ library in R was used to produce networks
for CPA or NHMRC funding.
RESULTS
CPARF funding
The total CPARF philanthropic funding for CP research
in Australia (2005–2015, ﬁgure 1) is $21 905 997 and
allocated as: (1) $7 073 638 to support people and infra-
structure forming the Cerebral Palsy Alliance Research
Institute; (2) $3 680 375 to Strategic Grants and (3)
$11 151 984 to Competitive Grants. Among the Strategic
Grants, the key funding allocations included the: 2009
International CP Conference held in Sydney, Australia;
establishment of the CP Registers, including database
development and people support and the strategic focus
from 2015 on stem cells and genomics for the future
prevention and cure of CP. Among the Competitive
Grants, $686 084 was contributed directly to the
NHMRC to support cofunded NHMRC doctoral scholar-
ships (n=7) and fellowships (n=2, 2014–2015) to build
capacity among CP researchers.
NHMRC funding by health condition
From 2000 to 2014, NHMRC funding for CP research
increased in real terms (ﬁgure 2). From the NHMRC
database for disease and health issues,16 CP funding is
comparable with other related health conditions: (1) CP
and autism are included under developmental disorders
and disability; (2) CP and Parkinson’s disease are
included under nervous system (Neuroscience) disor-
ders; and (3) cystic ﬁbrosis and childhood diabetes are
comparable with CP as they are also a lifelong condition
diagnosed in childhood.
In 2012, the NHMRC funding for all people living
with the respective condition was: AU$2.2 million for
CP; AU$4.3 million for autism; AU$3.3 million for cystic
ﬁbrosis; AU$7.7 million for Parkinson’s disease and AU
$6.3 million for childhood diabetes.16 For an individual
person living with the respective condition, this equated
to NHMRC funding of: AU$64 for CP; AU$67 for
autism; AU$1046 for cystic ﬁbrosis; AU$154 for
Parkinson’s disease and AU$1097 for childhood
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Figure 1 Cerebral Palsy Alliance Research Foundation total funding, 2005–2015; linear trend for total expenditure shown as a
straight, dotted line. The funding amounts are in dollar values for the year the total funding was awarded.
Figure 2 National Health and Medical Research Council Funding by Health Condition: cerebral palsy and comparable childhood
or neurological conditions. The funding amounts are in dollar values for the year the total funding was awarded.
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diabetes. In comparison, NIH funding in 2014 for an
individual person living with the condition equated to
US$27 for CP, US$53 for autism and US$2566 for cystic
ﬁbrosis.13
Competitive grants
The funding for CP research in Australia (2000–2015) is
compared between the philanthropic CPARF, and the
major government funding bodies NHMRC and ARC
(ﬁgure 3). From 2005 to 2015, the CPARF funded 102
grants: People (n=27) and Project (n=75). The total
amount spent on competitive grants was $10 645 900 (in
2015 dollars after adjustment for inﬂation is $11 209
557). There was relatively large variability in funding
over time. In 2011 and 2012, the funding levels dipped,
but increased greatly from 2013 to 2015. The CPARF
average total amount invested per year was $878 094.
From 2000 to 2015, the NHMRC funded 125 grants
for CP research, as identiﬁed from the spreadsheets
(n=105), ﬁnal reports (n=2) or both (n=18); and sum-
marised into People (n=51), Project (n=67) or Centre
(n=7). The total NHMRC funding spent on CP research
was $53 533 966 (in 2015 dollars after adjustment for
inﬂation is $63 035 914). Six ARC grants were related to
CP research and included the areas of citizenship and
independent living: People (n=1) and Project (n=5).
The ARC total amount spent on CP research was
$1 541 956 (in 2015 dollars after adjustment for inﬂation
is $1 706 647). Due to the low number of ARC grants for
CP research, the analysis is limited for any comparisons
with CPARF or NHMRC.
NHMRC and CPARF sources of competitive funding
show a general upward trend in funding with some
boom years (ﬁgure 3). The large correlation between
the NHMRC and CPARF (r=0.84, p=0.002) is partly
driven by the steady rise over time for both funding
agencies. For comparison purposes, ﬁgure 3 includes
the total funding awarded from the CPARF (total from
ﬁgure 1) and the total NHMRC funding for CP as the
target health condition nominated by CP researchers in
their original applications (total from ﬁgure 2, $26
million from 2000 to 2015). This analysis identiﬁed far
more CP funding by the NHMRC ($53.5 million) com-
pared with the data set prepared by the NHMRC based
speciﬁcally on health conditions nominated by the
researchers; a difference of over $27 million in identi-
ﬁed grants.
Comparison with NIH
The NIH funding is shown in terms of award year rather
than expenditure year as provided by Wu et al.12
Funding for CP in the USA has greatly increased in real
terms (ﬁgure 4). The mean increase in funding per year
was: $105 000 for NHMRC funding, $184 000 for CPARF
funding and US$ $4.9 million per year for NIH funding.
The increase in funding over time was statistically signiﬁ-
cant for the NIH (mean $4.9million, 95% CI 3.6M to
6.2M, p<0.001), but not for the NHMRC (mean $104K,
95% CI −77K to 287K, p=0.2) and CPARF (mean $184K,
95% CI −10K to 379K, p=0.06).
In the USA, funding for CP has also increased in
terms of the per cent overall share of the NIH budget.
Figure 3 Total funding for cerebral palsy research in Australia (2000–2015): Cerebral Palsy Alliance Research Foundation
(CPARF, competitive and total), National Health and Medical Research Council (original applications and categorised by cerebral
palsy) and Australian Research Council (original applications). The funding amounts are in 2015 dollars as adjusted for inflation
for the year of expenditure of funding.
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The increasing per cent share of NIH budget allocated
to CP research over time was statistically signiﬁcant
(mean 0.02%, 95% CI 0.02% to 0.03%, p<0.001),
whereas the NHMRC change over time was close to zero
(mean −0.002%, 95% CI −0.03% to 0.02%, p=0.9).
The average annual per cent of the NHMRC
budget allocated to CP research from 2000 to 2015
remained relatively ﬂat at 0.5%.
Network analysis
The CPARF and NHMRC network analysis (ﬁgure 5)
shows a number of small groups of 3–6 researchers,
based on individual grants. The largest CPARF network
is three groups joined through a single high-earning
researcher (number 14). The largest NHMRC network
is 18 researchers joined by four key linking researchers
(numbers 1, 2, 6 and 17). The network analysis indicates
most CP researchers are connected through collabora-
tions for funding. CPARF connections are broader com-
pared with the tighter established teams obtaining
NHMRC funding. Further, there are more ‘islands’
among the CPARF network indicating the new research-
ers entering the CP research ﬁeld, as compared with the
fewer ‘islands’ in the NHMRC network. Two ‘islands’ in
the network analysis of NHMRC funding include two
relatively successful researchers (numbers 8 and 9
winning four and eight grants, respectively) who are at
the centre of small networks that are not linked to the
main network.
DISCUSSION
In Australia, funding for CP research from the major
competitive grant schemes has stabilised in the last
decade. Historically, there have been irregular patterns
of funding and as a consequence there is a heavy reli-
ance on philanthropic donations to ﬁll the gap. As there
is a relatively small number of CP researchers in
Australia, and because NHMRC success rates are low
(currently under 15%), the annual funding awarded is
sporadic. Researchers try 1 year and if they miss out,
they need to resubmit the following year.21 22 This
results in irregular funding patterns for NHMRC money
and subsequent impacts on maintaining research
momentum. In the USA, the NIH is funding a larger
number of CP researchers and their funding pattern is
consistently increasing. CP needs to be a focus for the
NHMRC to provide consistent funding to achieve the
priorities highlighted by Australian families living with
CP.10
It is intriguing how the ups and downs in NHMRC
funding are mirrored by the CPARF (with a strong cor-
relation between the two amounts). A possible
Figure 4 Total funding for
cerebral palsy research by
National Health and Medical
Research Council (NHMRC,
Australia), Cerebral Palsy Alliance
Research Foundation (CPARF,
Australia) and National Institutes
of Health (NIH, USA): (A) total
dollars awarded per year and (B)
percentage of total funding
budget. Linear trend shown as
straight line; adjusted for inflation.
NIH data provided by Wu et al.12
The funding amounts are in 2015
dollars as adjusted for inflation for
the year of expenditure of funding
for NHMRC and CPARF, and
year awarded for NIH. (A) Total
funding $. (B) Per cent of total
budget
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Figure 5 Network diagram of
anonymised cerebral palsy
researchers by funding agency in
Australia. Researchers are
numbered according to their
overall income with 1 the highest
earner. (A) Funded by Cerebral
Palsy Alliance Research
Foundation. Lowest earner: 185.
Largest network through: 14.
(B) Funded by National Health
and Medical Research Council.
Lowest earner: 169. Largest
networks through: 1, 2, 6 and 17.
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explanation for this pattern is that CP researchers
submit a similar application to both agencies, with
researcher’s preference to obtain NHMRC funding to
build their track records and CPARF picks up the ‘fund-
able but not funded’ applications, that is, NHMRC appli-
cations deemed worthy of funding but the budget was
unavailable.17 The distinction between the number of
successful NHMRC research proposals that were ‘new’
versus resubmissions of previously unsuccessful applica-
tions could not be determined.21 22 An alternative
explanation is that NHMRC grant review panels may
have contained more CP experts in some years com-
pared with others. We examined the NHMRC peer
review honour roll to see if we could quantify this for CP
experts, but the data deﬁnitions were inconsistent.
Another explanation is that applicants may not submit
in some years because the application process takes an
average of 1–2 months of research time,21 22 and this
could result in the oscillating success patterns especially
as the CP community is small and well connected
(ﬁgure 5). Further, funding success in the previous year
may defer applications in the following year as the CP
researchers focus on their current projects.
The network analysis highlights the small number of
CP researchers in Australia. The limited number of
‘islands’ (or silos unconnected to other silos) show most
CP researchers are connected through their collabora-
tions; these networks enable research success.4 The
similar patterns for NHMRC and CPARF networks are
due to the majority of CP researchers being in both
groups. The CPARF works to expand networks and
promote collaborations, for example, hosting the
International CP Conference in 2009, and later that year
appointing the world’s ﬁrst Professorial Chair of
Cerebral Palsy. Hence, there was a peak in CPA funding
in 2009, followed by a temporary drop in 2010–2011 as
momentum was built for consistent funding. The small
community of CP researchers adapted to being able to
obtain CPARF funding and, where possible, CPARF
funded what the NHMRC did not fund; both funding
bodies were building research momentum for CP.
In the NHMRC funding network, there are relatively
successful researchers at the centre of a small network
that is not linked to the main community of CP
researchers. This is surprising given that these research-
ers were successful in winning multiple grants. One
potential explanation is the relatively common practice
among Australian health and medical researchers of
deliberately avoiding collaborations in order to have a
qualiﬁed reviewer available to assess grant applications.
The NHMRC uses strict conﬂict of interest rules,
meaning any previous collaborators are unable to review
your grant. In a small community of CP researchers, this
can mean that grant applications are reviewed by
researchers working in other ﬁelds who may not be able
to recognise the novelty or importance of the proposed
research. Another potential explanation is that the
unconnected networks indicate researchers from quite
different ﬁelds of research and expertise which limits
collaborations across the CP research community.
These ﬁndings are an underestimate of CP funding as
the search for grants was based on strict keyword search.
CP researchers may have a better chance of being
funded by the NHMRC if they use broader terms, such
as brain injury or neonatal intensive care, rather than
the speciﬁc focus on CP. With broader search terms
more grants would have been identiﬁed as being rele-
vant to CP research. Interestingly, the ﬁndings from this
study identiﬁed more than double the amount of
NHMRC funding as reported by the NHMRC speciﬁcally
for CP.16 This shows the value of looking through the
grants summaries in detail rather than only relying on
the key words. The identiﬁcation of only six ARC grants
for this analysis may be explained by the speciﬁc exclu-
sion of medical and clinical research and focus of ARC
funding for disabilities more generally, such as research
into social inclusion, community participation and
quality of life. Beyond inclusion in this study, other
NHMRC grants and many more ARC grants would
examine CP within a broader banner of disabilities.
The comparison between Australia and the USA is
limited to competitive grants only due to the exclusion
of USA philanthropic funding bodies. The analysis was
limited to the competitive grants awarded by CPARF for
comparison with NHMRC competitive grants. The add-
itional philanthropic funding by CPARF is included in
ﬁgure 3 as the line ‘CPARF Total’ to indicate the amount
of additional activity funded by CPARF beyond competi-
tive grants. There is overlap in philanthropic funding
between countries as CPARF has collaborated on funding
projects in the USA through PCORI and the American
Academy of Cerebral Palsy and Developmental Medicine,
and has initiated funding projects directly in the USA
from 2016. The limitation of the analysis extends to the
exclusion of other philanthropic or charitable organisa-
tions in Australia that contribute funding to people living
with CP.
In the context of the economic impact of CP on the
Australian community, of the $4 billion spent annually,9
the cumulative spend in this study of $77 million repre-
sents 0.2% of the economic costs across 10 years. By way
of comparison, in 2005 the global spend on cancer
research as funded by government and philanthropy was
estimated as 14 billion Euros and has resulted in great
gains in cancer treatments.3 In the USA, the NIH is con-
sistently increasing the funding pattern for CP research.
In Australia, the NHMRC needs to provide consistent
funding to achieve the research priorities of prevention
and cure of CP. Substantial future investment is needed
by government and philanthropy to provide signiﬁcant
increased funding for CP research. A concerted global
effort could further decrease the worldwide impact of
this lifelong condition on families;23 however, further
research cannot occur without further funding.
8 Herbert DL, et al. BMJ Open 2016;6:e012924. doi:10.1136/bmjopen-2016-012924
Open Access
group.bmj.com on October 25, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
Twitter Follow Adrian Barnett at @aidybarnett
Acknowledgements The authors would like to thank Anisa Rowhani-Farid
(QUT) for her assistance with extracting the NHMRC and ARC data from
publicly available datasets and reports, and preparing the final report to
Cerebral Palsy Alliance Research Foundation that formed the basis for this
study. The authors would like to thank Yvonne Wu for her generosity to share
her summary on NIH data for inclusion in this study.
Contributors DLH and AGB conceived and designed the study, collated and
analysed the descriptive data. AGB analysed the data to compare funding
schemes and conduct the network analysis. All authors interpreted the data,
drafted the article or revised it critically for important intellectual content and
approved the version to be published. DLH is the study chief investigator and
guarantor.
Funding This study was funded by the Cerebral Palsy Alliance Research
Foundation (PG0115).
Competing interests All authors have completed the ICMJE uniform
disclosure form at http://www.icmje.org/coi_disclosure.pdf and declare: DLH
is a former employee of Cerebral Palsy Alliance. AGB received funding from
CPARF for this study, and NHMRC funding for other research. RW and IN are
currently employed by Cerebral Palsy Alliance. NB holds the position of
Professorial Chair of Cerebral Palsy as financially supported by the CPARF. IN
and NB have received NHMRC funding for other research.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement NHMRC, ARC and NIH data are available from the
respective websites. CPARF and full data sets (with some blinding to preserve
anonymity) are available from the corresponding author.
Open Access This is an Open Access article distributed in accordance with
the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license,
which permits others to distribute, remix, adapt, build upon this work non-
commercially, and license their derivative works on different terms, provided
the original work is properly cited and the use is non-commercial. See: http://
creativecommons.org/licenses/by-nc/4.0/
REFERENCES
1. Wooding H, Hanney S, Pollitt A, et al. Project Retrosight:
understanding the returns from cardiovascular and stroke research:
the policy report. Europe: RAND Corporation. 2011. http://www.rand.
org/pubs/monographs/MG1079.html
2. Rottingen JA, Regmi S, Eide M, et al. Mapping of available health
research and development data: what’s there, what’s missing, and
what role is there for a global observatory? Lancet
2013;382:1286–307.
3. Eckhouse S, Lewison G, Sullivan R. Trends in the global
funding and activity of cancer research. Molec Oncol
2008;2:20–32.
4. Stuss DT. From silos to systems: an integrated approach to
neuroscience innovation. Nature Rev Drug Dis 2015;14:295–6.
5. Pinto D, Martin D, Chenhall R. The involvement of patient
organisations in rare disease research: a mixed methods study in
Australia. Orphanet J Rare Dis 2016;11:2.
6. Christensen D, Van Naarden Braun K, Doernberg NS, et al.
Prevalence of cerebral palsy, co-occurring autism spectrum
disorders, and motor functioning—Autism and Developmental
Disabilities Monitoring Network, USA, 2008. Dev Med Child Neurol
2014;56:59–65.
7. Smithers-Sheedy H, McIntyre S, Gibson C, et al. A special
supplement: findings from the Australian Cerebral Palsy Register,
birth years 1993 to 2006. Dev Med Child Neurol 2016;58(Suppl
2):5–10.
8. Reid SM, Meehan E, McIntyre S, et al. Temporal trends in cerebral
palsy by impairment severity and birth gestation. Dev Med Child
Neurol 2016;58(Suppl 2):25–35.
9. Access Economics. The economic impact of cerebral palsy in
Australia in 2007. Canberra: Access Economics, 2008. https://www.
deloitteaccesseconomics.com.au/uploads/File/The%20economic%
20impact%20of%20cerebral%20palsy%20in%20Australia%20in%
202007.pdf
10. McIntyre S, Novak I, Cusick A. Consensus research priorities for
cerebral palsy: a Delphi survey of consumers, researchers, and
clinicians. Dev Med Child Neurol 2010;52:270–5.
11. Novak I, Hines M, Goldsmith S, et al. Clinical prognostic messages
from a systematic review on cerebral palsy. Pediatrics 2012;130:
e1285–312.
12. Wu YW, Mehravari AS, Numis AL, et al. Cerebral palsy research
funding from the National Institutes of Health, 2001 to 2013. Dev
Med Child Neurol 2015;57:936–41.
13. Habiby J, Aisen M. More funding, better lives: the case for
cerebral palsy research. Dev Med Child Neurol 2015;57:
892–3.
14. McLeod N. Nothing is impossible: adventures in cerebral palsy.
Sydney: The Spastic Centre NSW, 2007. https://www.
cerebralpalsy.org.au/wp-content/uploads/2013/07/Nothing-is-
impossible.pdf
15. Cerebral Palsy Alliance Research Foundation. 10 years of
discovery dedicated to prevention, treatment and cure. Sydney:
CPA, 2015. https://research.cerebralpalsy.org.au/funding/
annual-reports/
16. National Health and Medical Research Council. NHMRC Research
funding 2005–2014: disease and health issues based datasets.
Canberra, Australia, 2015. http://www.nhmrc.gov.au/grants-funding/
research-funding-statistics-and-data
17. National Health and Medical Research Council. NHMRC Grants
2000–2014 (Updated July 2015). Canberra, Australia: NHMRC,
2015. http://www.nhmrc.gov.au/grants-funding/research-funding-
statistics-and-data
18. Australian Research Council. Definition of Medical and Dental
Research Version 2013.1, 2015. http://www.arc.gov.au
19. Australian Bureau of Statistics. 6401.0—Consumer Price Index,
Australia, Mar 2016. Canberra: ABS, 2016. http://www.abs.gov.au/
ausstats/abs@.nsf/mf/6401.0
20. Csardi G, Nepusz T. The igraph software package for complex
network research. Inter J Complex Syst 2006;1695:1–9.
21. Herbert DL, Barnett AG, Clarke P, et al. On the time spent preparing
grant proposals: an observational study of Australian researchers.
BMJ Open 2013;3:e002800.
22. Barnett AG, Graves N, Clarke P, et al. The impact of a
streamlined funding application process on application time: two
cross-sectional surveys of Australian researchers. BMJ Open
2015;5:e006912.
23. Richards WB. First Person. Lifestyles Magazine 2016;
Pre-Spring:22–26. http://www.lifestylesmagazine.com/website/
magazine.html
Herbert DL, et al. BMJ Open 2016;6:e012924. doi:10.1136/bmjopen-2016-012924 9
Open Access
group.bmj.com on October 25, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
2015: an observational study−Australia, 2000
 Funding for cerebral palsy research in
D L Herbert, A G Barnett, R White, I Novak and N Badawi
doi: 10.1136/bmjopen-2016-012924
2016 6: BMJ Open 
 http://bmjopen.bmj.com/content/6/10/e012924
Updated information and services can be found at: 
These include:
References
 #BIBLhttp://bmjopen.bmj.com/content/6/10/e012924
This article cites 14 articles, 3 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by-nc/4.0/non-commercial. See: 
provided the original work is properly cited and the use is
non-commercially, and license their derivative works on different terms, 
permits others to distribute, remix, adapt, build upon this work
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
This is an Open Access article distributed in accordance with the Creative
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (495)Research methods
 (508)Paediatrics
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on October 25, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
